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Introduction: We studied associations of the stress hormones copeptin and cortisol with outcome and organ
dysfunction after out-of-hospital cardiac arrest (OHCA).
Methods: Plasma was obtained after consent from next of kin in the FINNRESUSCI study conducted in 21 Finnish
intensive care units (ICUs) between 2010 and 2011. We measured plasma copeptin (pmol/L) and free cortisol (nmol/L)
on ICU admission (245 patients) and at 48 hours (additional 33 patients). Organ dysfunction was categorised with
24-hour Sequential Organ Failure Assessment (SOFA) scores. Twelve-month neurological outcome (available in
276 patients) was classified with cerebral performance categories (CPC) and dichotomised into good (CPC 1 or 2) or
poor (CPC 3 to 5). Data are presented as medians and interquartile ranges (IQRs). A Mann–Whitney U test, multiple linear
and logistic regression tests with odds ratios (ORs) 95% confidence intervals (CIs) and beta (B) values, repeated measure
analysis of variance, and receiver operating characteristic curves with area under the curve (AUC) were performed.
Results: Patients with a poor 12-month outcome had higher levels of admission copeptin (89, IQR 41 to 193 versus 51,
IQR 29 to 111 pmol/L, P = 0.0014) and cortisol (728, IQR 522 to 1,017 versus 576, IQR 355 to 850 nmol/L, P = 0.0013).
Copeptin levels fell between admission and 48 hours (P <0.001), independently of outcome (P = 0.847). Cortisol levels
did not change between admission and 48 hours (P = 0.313), independently of outcome (P = 0.221). The AUC for
predicting long-term outcome was weak for copeptin (0.62, 95% CI 0.55 to 0.69) and cortisol (0.62, 95% CI 0.54 to 0.69).
With logistic regression, admission copeptin (standard deviation (SD) increase OR 1.4, 95% CI 1.03 to 1.98) and cortisol
(SD increase OR 1.5, 95% CI 1.1 to 2.0) predicted ICU mortality but not 12-month outcome. Admission factors correlating
with SOFA were shockable rhythm (B −1.3, 95% CI −2.2 to −0.5), adrenaline use (B 1.1, 95% CI 0.2 to 2.0), therapeutic
hypothermia (B 1.3 95% CI 0.4-2.2), and copeptin (B 0.04, 95% CI 0.02 to 0.07).
Conclusions: Admission copeptin and free cortisol were not of prognostic value regarding 12-month neurological
outcome after OHCA. Higher admission copeptin and cortisol were associated with ICU death, and copeptin predicted
subsequent organ dysfunction.* Correspondence: markus.skrifvars@hus.fi
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Cardiac arrest is a devastating condition associated with
high mortality and morbidity [1]. After the return of
spontaneous circulation (ROSC), a pathophysiological
state recently named ‘post-cardiac arrest syndrome’ is
frequently observed, including myocardial dysfunction
with circulatory shock and evolving brain injury [2,3]. In
all types of critical illness, a stress response, accompan-
ied by activation of the hypothalamic-pituitary-adrenal
(HPA) axis and release of the hormone arginine-
vasopressin (AVP), is seen [4,5]. Activation of the HPA
axis results in the secretion of the adrenocorticotropic
hormone (ACTH), which stimulates the medulla to syn-
thesise cortisol [6]. Relative adrenal insufficiency is com-
mon following cardiac arrest and seems to be related to
the severity of the ischaemic insult [7].
Copeptin is the C-terminal part of the AVP precursor
pro-AVP [8]. Copeptin is stable and fairly easy to meas-
ure as opposed to AVP. Studies have shown that copep-
tin is an accurate marker of both disease severity and
survival in various conditions, such as myocardial infarc-
tion, heart failure, and stroke [9-11]. Two small pilot tri-
als have indicated excellent prognostic accuracy of
copeptin in patients admitted to the intensive care unit
(ICU) following out-of-hospital cardiac arrest (OHCA)
[12,13]. Accordingly, the aim of the present study was to
evaluate the accuracy of circulating copeptin levels at ad-
mission and 48 hours later in the prediction of long-term
neurological outcomes after OHCA. For comparison, we
studied free cortisol as a marker of HPA axis activation.
We further sought to study the associations with admission
levels of copeptin and cortisol and the severity of subse-
quent organ dysfunction.
Methods
Patient group
The patients included in this study were part of the
FINNRESUSCI study, which was a prospective observa-
tional cohort study that was conducted at 21 hospitals in
Finland between 1 March 2010 and 28 February 2011
and that included 548 patients [14]. The study was ap-
proved by the ethics committee of the Helsinki and
Uusimaa Hospital district (FINNRESUSCI TUTKIMUS
§10, 20.1.201) in addition to local ethics approvals in
six of the hospitals (listed in the Appendix). Informed
consent was obtained from the next of kin prior to
obtaining blood samples. Informed consent was ob-
tained for 245 patients at the time of ICU admission
and for an additional 33 patients prior to additional
sampling 48 hours later, giving a total study sample of
278 patients. Information on the 12-month neuro-
logical outcome was available for 276 patients. Thus,
these 276 patients were included in the long-term out-
come analysis.Assay of circulating stress markers
Blood samples were collected in ethylenediaminetetra-
acetic acid tubes and centrifuged, and the plasma was
stored at −70°C. Upon analysis, the samples were thawed
and divided into aliquots. The plasma concentration of
cortisol was measured by a chemiluminescent immuno-
assay on an Access 2 instrument (Beckman Coulter S.p.A.,
Cassina De’ Pecchi, Italy). The imprecision of the assay
was less than 10%. The reference ranges for plasma corti-
sol were 185 to 624 nmol/L (morning) and less than
276 nmol/L (post-meridiem). The concentrations of copep-
tin were assayed by using an immunofluorescent immuno-
assay (Copeptin; Brahms, Henningsdorf, Germany) with
an automated Kriptor Analyzer (Thermo Fisher Scientific,
Milan, Italy). The limit of detection was 0.9 pmol/L, and
the lower concentration measurable with a coefficient of
variation of less than 10% was less than 4 pmol/L. The
95th percentile calculated in healthy donors was less than
12 pmol/L. All of the assays were performed in a centra-
lised laboratory by personnel blinded to the clinical
characteristics and patient outcome.Data collection
All the participating hospitals are part of the Finnish In-
tensive Care Consortium, and all the ICUs, except one,
use the same electronic data management systems and
data validation software (Web Validator; Tieto, Helsinki,
Finland). Patient data were collected prospectively by
using internet-based case report forms. Pre-hospital data
were collected by paramedics in accordance with the
Utstein guidelines and included factors such as whether
the arrest was witnessed, the administration of bystander-
initiated life support, time from the call to the dispatch
centre and the ROSC, and the use of adrenaline [15]. In-
hospital care data were collected electronically and in-
cluded the Simplified Acute Physiology Score II (SAPS
II) and ICU and hospital mortality. The Sequential
Organ Failure Assessment (SOFA) score was used as a
measure of organ function during the first 24 hours of
ICU care.Survival and 12-month neurological outcomes
The time of death was recorded for each patient. A spe-
cialist in neurology (MT) who was blinded to the ICU
care and blood test results evaluated the patient’s neuro-
logical outcome according to the Pittsburgh Cerebral
Performance Category (CPC) [15]. A good outcome was
defined as a CPC of 1 or 2, and a poor outcome was
classified as a CPC of 3 to 5. Patients or their next of kin
were contacted by phone, and the outcome was deter-
mined in a structured fashion. If a patient was hospital-
ized or in a nursing home, nursing staff or relatives were
contacted by phone.
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Descriptive statistics are expressed with counts and per-
centages for categorical variables and median values with
the interquartile range (IQR) for continuous variables.
The levels of plasma copeptin and free cortisol on ad-
mission were compared with the Mann–Whitney U test,
and changes over time between admission and 48 hours
later were assessed with a repeated measures analysis of
variance. We used the appropriate correction for a non-
normal distribution, if needed, and analysed the differ-
ences between those with a good and a poor outcome
and the interaction with time. Correlations between ad-
mission factors and subsequent 24-hour SOFA scores
were analysed with univariate and multiple linear regres-
sion with corresponding beta values and 95% confidence
intervals (CIs). Multi-variable logistic regression was
used to identify factors at admission that were independ-
ent predictors of ICU mortality and a good outcome at
12 months. All of the variables associated with the out-
come in the univariate analysis (P <0.05) and factors
found to be relevant in previous OHCA studies were in-
cluded in the multiple linear and logistic regression
models. The prognostic discrimination of copeptin and
cortisol for 12-month outcomes was investigated by
using receiver operating characteristic (ROC) curves,
with the corresponding area under the curve (AUC). We
compared the AUCs by using a bootstrap method (2,000
samples) [16]. Odds ratios (ORs) with their correspond-
ing 95% CIs were calculated, and P values were consid-
ered statistically significant if they were less than 0.05.
All statistical analyses were performed with SAS soft-
ware, version 9.2 (SAS Institute, Inc., Cary, NC, USA),
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA), and
GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla,
CA, USA).
Results
Of the included 278 patients, 183 (66%) had a cardiac ar-
rest with an initial shockable rhythm, and 95 (34%) had
a non-shockable rhythm. The majority of the patients
(n = 202, 73%) were treated with therapeutic hypothermia
(TH), and 76 (27%) were not. Of the 278 patients, 229
(82%) survived to ICU discharge, 170 (59%) survived to
hospital discharge, and 143 (52%) of the patients were
alive at 12 months. Of the 143 patients who survived
12 months, 133 (48% of the total 276 resuscitated patients)
had a favourable neurological outcome (CPC of 1 or 2).
Long-term data were not available in two patients.
Among the 183 patients with a shockable rhythm, 166
(91%) survived to ICU discharge, and 110 (60%) had a
good neurological outcome at 12 months. Among the 95
patients with a non-shockable rhythm, 63 (69%) survived
to ICU discharge, and 23 (24%) had a good 12-month
neurological outcome (long-term outcome data missingfor one patient). Several factors at resuscitation were as-
sociated with a higher likelihood of ICU survival. These
included a shockable initial rhythm, no use of adren-
aline, a shorter delay to ROSC, and treatment with TH
(Table 1). Factors correlated with a good 12-month out-
come were younger age, a shockable rhythm, witnessed
arrest, no use of adrenaline, and a shorter time to ROSC
(Table 1). The results of the multiple logistic regression
models are shown in Tables 2 and 3.
Levels of copeptin and cortisol and patient outcomes
Median copeptin levels on admission were higher in pa-
tients who died in the ICU (148 pmol/L, IQR 58 to 291)
and in those with a poor 12-month outcome (89 pmol/L,
IQR 41 to 193) compared with those who survived to ICU
discharge (63 pmol/L, IQR 32 to 131) and those with a
good 12-month outcome (51 pmol/L, IQR 29 to 111) (P =
0.0009 and P = 0.0014). The differences in the levels of
copeptin measured at 48 hours were not significant
(Table 1). The levels of copeptin changed over time in
both groups (P <0.001), but the interaction between pa-
tient outcomes and time was not significant (P = 0.847)
(Figure 1). In the multi-variate analysis, copeptin was an
independent predictor of ICU survival but not 12-month
outcomes (Tables 2 and 3). The AUCs were 0.623 (0.553
to 0.693) for a poor 12-month outcome and 0.656 (0.558
to 0.754) for ICU mortality (Additional file 1). When only
the patients treated with TH were analysed, the corre-
sponding values were 0.63 (0.54 to 0.71) for long-term
outcome and 0.71 (0.59 to 0.83) for ICU mortality.
Median admission cortisol levels were higher in those
who died in the ICU (860 nmol/L, 627 to 1,119) and in
those with a poor outcome at 12 months (728 (522 to
1017), IQR 403 to 942) compared with those who survived
to ICU discharge (634 nmol/L, 378 to 876) and those with
a good 12-month outcome (576 (355 to 850), IQR 328 to
733). There was no significant change over time (P = 0.313)
and no interaction between time and outcome (P = 0.221)
(Figure 1). In the multi-variate analysis, cortisol was an in-
dependent predictor of ICU death but not of 12-month
outcomes (Tables 2 and 3). The AUCs were 0.624 (0.554
to 0.694) for a poor 12-month outcome and 0.662 (0.574
to 0.750) for ICU mortality (Additional file 1). When only
the TH patients were analysed, the corresponding figures
were 0.58 (0.50 to 0.66) for long-term outcomes and 0.61
(0.5 to 0.73) for ICU mortality. There was no difference in
the AUCs of copeptin and cortisol for ICU mortality (P =
0.91) or for poor 12-month mortality prediction (P = 0.97).
Copeptin, cortisol, and organ failure
Admission copeptin and cortisol levels indexed by the
severity of the subsequent SOFA score are shown in
Figure 2. Factors correlated with increased severity of organ
failure in the univariate analysis were a non-shockable
Table 1 Baseline characteristics and copeptin and cortisol levels of out-of-hospital cardiac arrest patients and short-term
and long-term outcomes
ICU non-survivors
(n = 49)
ICU survivors
(n = 229)
P value Poor 12-month
outcome (n = 143)
Good 12-month
outcome (n = 133)
P value
Patient factors
Age, years 64±14 63±12 0.191 65 (±13) 60 (±12) 0.0017
Male,% (n) 82% (40) 83% (189) 0.881 83% (119) 82% (109) 0.782
Factors at resuscitation
Shockable,% (n) 35% (17) 71 (163) <0.001 50% (71) 81% (108) <0.001
Time to ROSC, minutes 24 (20–31) 18 (12–26) <0.001 23 (18-30) 16 (11-23) <0.001
Adrenaline used, yes 92% (45) 62% (141) <0.001 83% (118) 50% (67) <0.001
ICU treatment
Therapeutic hypothermia,% (n) 59% (29) 76% (173) 0.020 68% (97) 78% (104) 0.053
Lowest 24-hour MAP, mm Hg 58 (41–64) 62 (58–68) <0.001 61 (55–67) 61 (57–68) 0.241
Highest 24-hour norepinephrine,
μg/kg per minute
0.18 (0–0.35) 0.06 (0–0.13) <0.001 0.07(0–0.19) 0.05 (0–0.14) 0.409
SAPS II 73 (64–81) 57 (39–66) <0.001 66 (57–73) 48 (34–63) <0.001
Biomarkers
Copeptin 0–6 hours, pmol/L 148 (58–291) 63 (32–131) 0.0009 89 (41–193) 51 (29–111) 0.0014
Copeptin 48 hours, pmol/L 20 (9–111) 20 (11–40) 0.3399 23 (13–44) 16 (10–46) 0.0702
Relative change in copeptin −45 (−166-(−13)) −38 (−100-(−11)) 0.502 −44 (−142-(−13)) −32 (−88-(7)) 0.152
Cortisol 0–6 hours, nmol/L 860 (627–1,119) 634 (378–876) 0.0006 728 (522–1,017) 576 (355–850) 0.0013
Cortisol 48 hours, nmol/L 627 (311–1,461) 548 (378–813) 0.4414 645 (403–942) 480 (328–733) 0.0053
Change in cortisol,% −115 (−592-253) −62 (−329-192) 0.419 −59 (−343-215) −65 (−331-194) 0.741
One hundred eighty-nine patients were included in the delta copeptin/cortisol analysis of 12-month outcomes, and 190 patients were included in the delta copeptin/
cortisol analysis of intensive care unit (ICU) mortality. MAP, mean arterial pressure; ROSC, return of spontaneous circulation; SAPS II, Simplified Acute Physiology Score II.
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and admission copeptin and cortisol levels (Table 4). In
the multiple linear regression, only a non-shockable
rhythm, adrenaline, use of TH, and admission copeptin
levels were independent predictors of a higher SOFA score
(Table 4).
Discussion
In this multi-centre study, we found that plasma copep-
tin and free cortisol levels were markedly increased inTable 2 Results of multi-variable regression analysis of factor
Variables Risk category Model 1 (with cor
OR (95% CI)
Age Increase/year 1.05 (1.03-1.08)
Witnessed arrest Yes 0.5 (0.15-1.5)
Initial rhythm Not shockable 4.5 (2.2-9.3)
Time to ROSC Increase/minute 1.08 (1.04-1.12)
Adrenaline Yes 2.5 (1.2-5.2)
Therapeutic hypothermia Yes 0.7 (0.3-1.5)
Cortisol Increase/SD 1.1 (0.8-1.5)
Copeptin Increase/SD -
CI, confidence interval; OR, odds ratio; ROSC, return of spontaneous circulation; SD,OHCA patients at the time of admission to the ICU.
The level of copeptin, but not that of free cortisol, nor-
malised at 48 hours independently of the patient out-
come. Plasma copeptin was an independent predictor of
organ dysfunction and ICU death but not of long-term
outcome. Copeptin, but not free cortisol, levels on ad-
mission correlated independently with the severity of
organ dysfunction.
Two previous small pilot studies on OHCA outcomes
and plasma copeptin levels were limited to patientss associated with a poor long-term neurological outcome
tisol) P value Model 2 (with copeptin) P value
OR (95% CI)
<0.001 1.05 (1.02-1.08) <0.001
0.210 0.5 (0.14-1.5) 0.194
<0.001 4.5 (2.2-9.3) <0.001
<0.001 1.07 (1.03-1.12) <0.001
0.019 2.4 (1.12-5.1) 0.024
0.321 0.7 (0.3-1.5) 0.33
0.535 - -
- 1.2 (0.8-1.8) 0.340
standard deviation.
Table 3 Results of multi-variable logistic regression analysis of intensive care unit mortality
Variables Risk category Model 1 (with cortisol) P value Model 2 (with copeptin) P value
OR (95% CI) OR (95% CI)
Initial rhythm Not shockable 3.9 (1.7-8.6) 0.0010 3.8 (1.7-8.5) <0.001
Time to ROSC Increase/minute 1.03 (0.99-1.07) 0.111 1.03 (0.99-1.06) 0.326
Use of adrenaline Yes 5.3 (1.5-19.1) 0.010 4.1 (1.3-13.3) 0.020
Therapeutic hypothermia Yes 0.6 (0.3-1.4) 0.1528 0.5 (0.2-1.3) 0.199
Cortisol Increase/SD 1.5 (1.1-2.0) 0.013 - -
Copeptin Increase/SD - - 1.4 (1.03-1.98) 0.034
CI, confidence interval; OR, odds ratio; ROSC, return of spontaneous circulation; SD, standard deviation.
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value of copeptin was good [12,13]. In a study of 40 pa-
tients, Ostadal et al. showed that copeptin had an AUC
of 0.801 for the prediction of 30-day mortality [12]. They
reported that a copeptin level exceeding a cutoff value of
217.9 pmol/L was significantly associated with increased
mortality at 30 days. Annborn et al. presented com-
parable findings in a study including 80 cardiac arrest
patients treated with TH [13]. In that study, copeptinFigure 1 Association of plasma copeptin and free cortisol values at th
Copeptin levels changed over time in both groups (P <0.001), with no interac
change over time (P = 0.313) and no interaction between time, patient outcomeasured at 12 hours had the best predictive power,
with an AUC of 0.85. Interestingly, in that study, there
was less overlap between patients with good and poor
outcomes 12 and 24 hours after cardiac arrest. It is con-
ceivable that the sampling times that we used in this
study were outside the optimal time interval for prog-
nostication using copeptin.
Organ dysfunction is common after cardiac arrest and
is correlated with survival [17]. Levels of inflammatorye time of admission and 48 hours later with 12-month outcomes.
tion between outcome and time (P = 0.847). There was no significant
mes (P = 0.221), and cortisol levels.
Figure 2 Plasma-free cortisol and copeptin values measured on admission and subsequent 24-hour Sequential Organ Failure Assessment
(SOFA) scores. Copeptin, but not cortisol, was an independent predictor of SOFA score in a multiple linear regression.
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with the severity of organ dysfunction in OHCA patients
treated with targeted temperature management [18,19].
The activation of the HPA axis is a crucial part of the
endocrine stress response, and several factors activate
the HPA axis. Interestingly, a recent study demonstrated
that global hypoxia stimulated copeptin release in an
experimental setting [20]. Upon exposure to hypoxia,
copeptin levels increased but returned to near normal
levels 16 hours later, despite continued exposure toTable 4 Factors associated with the first 24-hour Sequential O
Factors Univariab
Risk category Β (95% C
Age Per 10-year increase 0.193 (−0.
Gender Male 0.351 (−0.
Shockable initial rhythm Yes −1.530 (−2
Time to ROSC Per 10-minute increase 0.768 (0.43
Adrenaline Yes 1.939 (1.17
Bystander CPR Yes −0.126 (−0
Witnessed arrest Yes −0.498 (−1
Therapeutic hypothermia Yes 0.820 (−0.
Copeptin Per increase of 10 pmol/L 0.06 (0.038
Cortisol Per increase of 100 nmol/L 0.047 (0.00
CI, confidence interval; CPR, cardiopulmonary resuscitation; NI, not included; ROSC,hypoxia [20]. This is in line with the time pattern of
copeptin levels seen in the present study. Newborns
have high copeptin levels [21]. In patients with myocar-
dial infarction, copeptin levels are higher in those with
acute heart failure [22]. Cardiac arrest patients have both
severe hypotension and global hypoxia, both of which
may stimulate the release of AVP. The release of AVP is
further stimulated by inflammation and the release of in-
flammatory markers intereukin-1 and interleukin-6 [23].
Taken together, our findings suggest that copeptin releasergan Failure Assessment scores
le analysis Multi-variable analysis
I) P value Β (95% CI) P value
1-0.486) 0.195 0.02 (−0.08-0.47) 0.158
634-1.337) 0.484 NI NI
.301-0.758) <0.001 −1.34 (−2.16-(−0.51)) 0.002
7-1.099) <0.001 0.193 (−0.20-0.59) 0.338
4-2.704) <0.001 1.1 (0.22-1.99) 0.014
.884-0.633) 0.745 NI NI
.835-0.839) 0.464 NI NI
018-1.658) 0.055 1.27 (0.36-2.17) 0.006
-0.082) <0.001 0.043 (0.02-0.066) <0.001
1-0.093) 0.046 0.03 (−0.014-0.074) 0.179
return of spontaneous circulation.
Ristagno et al. Critical Care  (2015) 19:132 Page 7 of 8is induced mainly by the ischaemic insult in cardiac arrest
and that it may play a role in the evolution of organ dys-
function after cardiac arrest.
In the present study, cortisol levels were elevated and
remained so at 48 hours after admission to the ICU, cor-
roborating the findings of previous studies of cortisol
levels in patients with OHCA. Not only the release of
ACTH but also adrenal function influences cortisol
levels. Thus, low levels of free cortisol may suggest ad-
renal failure and may be a sign of a poor prognosis in
patients with OHCA, especially in response to increased
levels of ACTH [23,24]. The evidence for the value of
basal cortisol levels on admission after OHCA has been
conflicting; some studies indicate lower levels [7] and
others report higher levels [24,25] in survivors. In the
present study, plasma cortisol levels remained greatly el-
evated, even at 48 hours, in those with good and those
with poor outcomes.
Study strengths and limitations
The strengths of the present study include the study size
and multi-centre setting. First, the demographic data of
the study population suggest that our patient sample is
representative of the whole FINNRESUSCI OHCA popu-
lation and therefore has external validity. Second, the
primary outcome, 12-month CPC, was prospectively de-
termined by a researcher (MT) blinded to biomarker
levels and intensive care management. Nonetheless, this
study is not without limitations. First, owing to the ethical
requirement for informed consent prior to blood sam-
pling, not all patients could be included and there was a
variation in time from cardiac arrest to sampling. Second,
we measured plasma-free cortisol levels only. We did not
perform ACTH tests, as these are not recommended for
critically ill patients.
Conclusions
Higher plasma copeptin and free cortisol levels on ad-
mission after OHCA predicted ICU mortality but not
long-term neurological outcomes after OHCA, as re-
ported earlier in small cohort studies. The level of
copeptin on admission was associated with subsequent
organ dysfunction. Thus, it may have clinical value for
early triage decisions in patients at risk of developing
organ dysfunction associated with post-cardiac arrest
syndrome.
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 Copeptin measured at the time of ICU admission is
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 Copeptin is an accurate marker of ICU death and the
severity of organ dysfunction but is of limited value in
isolation for long-term neurological outcomes.
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